Literature DB >> 20839301

Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.

Eri Sano1, Weihua Li, Hitomi Yuki, Xinli Liu, Tomomi Furihata, Kaoru Kobayashi, Kan Chiba, Saburo Neya, Tyuji Hoshino.   

Abstract

Cytochrome P450 (CYP) is deeply involved in the metabolism of chemicals including pharmaceuticals. Therefore, polymorphisms of this enzyme have been widely studied to avoid unfavorable side effects of drugs in chemotherapy. In this work, we performed computational analysis of the mechanism of the decrease in enzymatic activity for three typical polymorphisms in CYP 2C9 species: *2, *3, and *5. Based on the equilibrated structure obtained by molecular dynamics simulation, the volume of the binding pocket and the fluctuation of amino residues responsible for substrate holding were compared between the wild type and the three variants. Further docking simulation was carried out to evaluate the appropriateness of the binding pocket to accommodate substrate chemicals. Every polymorphic variant was suggested to be inferior to the wild type in enzymatic ability from the structural viewpoint. F-G helices were obviously displaced outward in CYP2C9*2. Expansion of the binding pocket, especially the space near F' helix, was remarkable in CYP2C9*3. Disappearance of the hydrogen bond between K helix and β4 loop was observed in CYP2C9*5. The reduction of catalytic activity of those variants can be explained from the deformation of the binding pocket and the consequent change in binding mode of substrate chemicals. The computational approach is effective for predicting the enzymatic activity of polymorphic variants of CYP. This prediction will be helpful for advanced drug design because calculations forecast unexpected change in drug efficacy for individuals. 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20839301     DOI: 10.1002/jcc.21568

Source DB:  PubMed          Journal:  J Comput Chem        ISSN: 0192-8651            Impact factor:   3.376


  11 in total

1.  Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.

Authors:  Darcy R Flora; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2011-12-28       Impact factor: 3.922

Review 2.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

Review 3.  Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.

Authors:  Johannes Kirchmair; Mark J Williamson; Jonathan D Tyzack; Lu Tan; Peter J Bond; Andreas Bender; Robert C Glen
Journal:  J Chem Inf Model       Date:  2012-02-17       Impact factor: 4.956

4.  Distal effect of amino acid substitutions in CYP2C9 polymorphic variants causes differences in interatomic interactions against (S)-warfarin.

Authors:  Panida Lertkiatmongkol; Anunchai Assawamakin; George White; Gaurav Chopra; Pornpimol Rongnoparut; Ram Samudrala; Sissades Tongsima
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

5.  Discovery of a regioselectivity switch in nitrating P450s guided by molecular dynamics simulations and Markov models.

Authors:  Sheel C Dodani; Gert Kiss; Jackson K B Cahn; Ye Su; Vijay S Pande; Frances H Arnold
Journal:  Nat Chem       Date:  2016-03-21       Impact factor: 24.427

Review 6.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

7.  In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane.

Authors:  Amity Peterson; Zuping Xia; Gang Chen; Philip Lazarus
Journal:  Pharmacol Res Perspect       Date:  2017-04-27

8.  Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels.

Authors:  Parker W de Waal; Kyle F Sunden; Laura Lowe Furge
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

9.  Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9*30.

Authors:  Maxime Louet; Céline M Labbé; Charline Fagnen; Cassiano M Aono; Paula Homem-de-Mello; Bruno O Villoutreix; Maria A Miteva
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

10.  Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population.

Authors:  Shabbir Ahmed; Jie Zhou; Zhan Zhou; Shu-Qing Chen
Journal:  Genes (Basel)       Date:  2018-10-22       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.